Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ventral anterior homeobox 1 (VAX1) is a homeodomain-containing transcription factor encoded by the VAX1 gene, part of the homeobox gene family highly conserved in vertebrates. VAX1 plays a crucial regulatory role in the development of the anterior ventral forebrain, midline brain structures, and visual system; it is also essential for craniofacial morphogenesis. Mutations or deficiency in VAX1 in both humans and animal models cause developmental abnormalities, including microphthalmia (small eyes), cleft lip/palate, corpus callosum agenesis, and visual system defects. Expression is primarily in the forebrain and in developmentally relevant regions such as the palate, optic stalk, and visual eye fields. Recent findings also suggest secreted VAX1 has a non-transcriptional role as an axon growth factor for retinal ganglion cells, binding to heparan sulfate proteoglycans to guide axonal growth, a unique mechanism among transcription factors. VAX1 shows no known direct pharmacological targeting or interacting drugs and is not currently a therapeutic drug target; its relevance is primarily in developmental biology and human genetics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ventral anterior homeobox 1 (VAX1).